首页> 外文期刊>World journal of urology >Prostate cancer diagnostics: innovative imaging in case of multiple negative biopsies.
【24h】

Prostate cancer diagnostics: innovative imaging in case of multiple negative biopsies.

机译:前列腺癌诊断:多次阴性活检时的创新成像。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: According to international guidelines, a primary set of TRUS-guided systematic biopsy should consist of 10-12 tissue samples. If a clinical suspicion of a prostate carcinoma persists, a secondary biopsy session should also involve 10-12 samples. However, if there still is a clinical suspicion of prostate cancer is there a role for innovative imaging guided biopsies? MATERIALS AND METHODS: The available innovative imaging techniques range from MRI, Doppler techniques with and without contrast agents, a renaissance of elastography to computer-assisted evaluation of TRUS signal information. RESULT: All of these methods attempt to make more specific statements on the imaged tissue. Before routine clinical use, a review of the literature is recommended to be able to differentiate between the different methods. Sophisticated modern MRI techniques allow for excellent high-resolution prostate imaging. However, MRI guided biopsies so far are not routine practice and are not recommended in urological guidelines. A literature review reflects differences in stage of development, biopsy performance and clinical validity of the different imaging modalities. Elastography, contrast imaging and C-TRUS/ANNA guided biopsies have been investigated in clinical trails suggesting possible benefits over additional systematic random biopsies alone. Because of the differences in design and clinical maturity of the innovative imaging methods, it is essential to be able to inform the patients about individual evidence-based performance prior to its clinical utilization. CONCLUSION: The ideal time for innovative imaging techniques seems to be in patients with multiple series of negative systematic biopsies possibly leading to a more specific PCa detection. However, patients often ask for a qualitative diagnostic approach right from the beginning. This should only be performed after educating the patient on the experimental and 'non-guideline-conform' character of such a proceeding.
机译:目的:根据国际指南,一套由TRUS指导的系统活检应包括10-12个组织样本。如果仍然存在对前列腺癌的临床怀疑,则二次活检也应包括10-12个样本。但是,如果仍然存在前列腺癌的临床怀疑,那么创新的影像引导活检是否有作用?材料与方法:可用的创新成像技术包括MRI,有无造影剂的多普勒技术,弹性成像的复兴以及对TRUS信号信息的计算机辅助评估。结果:所有这些方法都试图在成像的组织上做出更具体的陈述。在常规临床使用之前,建议回顾一下文献,以便能够区分不同的方法。先进的现代MRI技术可实现出色的高分辨率前列腺成像。但是,迄今为止,MRI引导的活检不是常规做法,也不建议在泌尿科指南中使用。文献综述反映了不同成像方式在发展阶段,活检性能和临床有效性方面的差异。弹性成像,对比成像和C-TRUS / ANNA引导的活检已在临床试验中进行了研究,提示相对于单独的其他系统随机活检可能具有的益处。由于创新成像方法在设计和临床成熟度方面的差异,因此至关重要的是能够在临床应用之前告知患者有关个别循证医学表现。结论:创新影像学技术的理想时机似乎是在患有一系列阴性系统活检的患者中,可能导致更特异性的PCa检测。但是,患者常常从一开始就要求定性诊断方法。仅应在对患者进行此类过程的实验性和“非准则符合性”教育之后,才可以执行此操作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号